PreSize Net medical device software for realistic surgery planning: next-generation scalable technology for selecting the best surgical scenario for every patient

用于现实手术规划的 PreSize Net 医疗设备软件：下一代可扩展技术，可为每位患者选择最佳手术方案

• 批准号: 10055877
• 金额: $ 63.63万
• 依托单位: OXFORD HEARTBEAT LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10055877
• 关键词: PreSize; Net; medical; device; software

Our goal is to make cardiovascular surgeries more efficient and safe. This project increases the power of our PreSize medical device software - a novel clinical decision-support solution that helps surgeons plan and rehearse implant placements inside blood vessels with realistic surgery simulations. Using cutting-edge computational modelling, we make the best use of available patient scans and device mechanics to accurately predict the behaviour of devices inside each patient's vessel anatomy. This allows clinicians to select the best device for every patient, reducing the number of complications and associated cost of surgeries for hospitals and our society. What is especially innovative with this project is that the PreSize platform will be developed to be as easily accessible as possible, aimed to maximise its reach and benefits across the healthcare system.We are an award-winning start-up company specifically created to bring this technology to hospitals. With a strong team of engineering, software, commercial, legal and regulatory experts, we have been previously supported by Innovate UK grants (currently running BMC Early Stage award until April 2022) and receive ongoing support by The Royal Academy of Engineering. The results of our previous projects have received numerous awards, including:* NHS Innovation Award 2017 from Health Enterprise East (HEE)* "Best Healthcare Start-up of 2018" by WIRED magazine* BioMedEng Innovation Prize 2021 for recognition of our founder's 'ground-breaking work which has led to new technologies that support medical interventions'We were also selected to be part of the Digital Health London Accelerator programme, and were previously one of the 6 startups selected globally by Philips Healthcare Accelerator, as well as featured in the general press, e.g., in Forbes ("Founders striving to change the world") and WIRED ("From AI doctors to 3D X-rays, the future of healthcare is already here"), as well as The Times, Financial Times, The Telegraph, etc.Our aim is to grow Oxford Heartbeat to become the leading provider of clinical decision support tools, to boost the UK economy and its international leadership in healthcare, to improve healthcare for all, and define the medicine of tomorrow.

我们的目标是使心血管手术更加高效和安全。该项目增强了我们PreSize医疗器械软件的功能-这是一种新型的临床决策支持解决方案，可帮助外科医生通过逼真的手术模拟计划和演练血管内的植入物放置。使用尖端的计算建模，我们充分利用可用的患者扫描和器械力学，以准确预测每个患者血管解剖结构内器械的行为。这使临床医生能够为每位患者选择最佳设备，减少并发症的数量以及医院和社会的相关手术成本。该项目的创新之处在于，PreSize平台将尽可能易于使用，旨在最大限度地扩大其在整个医疗系统中的覆盖面和效益。我们是一家屡获殊荣的初创公司，专门为将这项技术引入医院而创建。凭借强大的工程、软件、商业、法律的和监管专家团队，我们之前一直获得英国创新赠款的支持（目前正在运行BMC早期奖，直到2022年4月），并得到皇家工程学院的持续支持。我们之前的项目成果获得了众多奖项，其中包括：* Health Enterprise East（HEE）颁发的2017年NHS创新奖 *《连线》（WIRED）杂志颁发的“2018年最佳医疗初创企业”* 2021年BioMedEng创新奖，以表彰我们创始人“开创性的工作，这些工作带来了支持医疗干预的新技术”我们还被选为数字健康伦敦加速器计划的一部分，并且曾是飞利浦医疗加速器在全球范围内选择的6家初创企业之一，并在大众媒体上进行了报道，例如，在福布斯（“努力改变世界的创始人”）和《连线》杂志（“从人工智能医生到3D X射线，医疗保健的未来已经在这里”），以及《泰晤士报》，《金融时报》，《每日电讯报》等。我们的目标是发展牛津心跳成为临床决策支持工具的领先提供商，促进英国经济及其在医疗保健领域的国际领导地位，改善全民医疗保健，并定义未来的医学